Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug
Gilead Sciences has agreed to pay $40m (£31.5m; €37m) to about 2600 patients who developed…
Category: US, HIV/AIDS
Gilead Sciences has agreed to pay $40m (£31.5m; €37m) to about 2600 patients who developed…